Latest Stories
Featured Stories
Explore inspiring journeys of recovery and resilience as patients share their experiences with Padaav’s root-cause-focused, evidence-based Ayurvedic treatments, highlighting the power of personalized care and holistic healing.
Feedback
All Stories
Delve into the heartfelt experiences of patients who have transformed their health and lives with Padaav’s research-backed Ayurvedic care, showcasing the impact of addressing root causes for lasting recovery.
Hamad Alam
Rectal Adenocarcinoma
New Delhi
Hamad’s struggle reached a terrifying peak in 2018 while traveling back to Delhi from a cou…
Patient Name
Acute Recurrent Pancreatitis
Kotdwar, Uttarakhand.
Shilpi’s struggle began suddenly during her 10th-grade school break, when she felt a sharp …
Anurag Goyal
Investment Banker
New Delhi
Anurag’s struggle began suddenly in the midnight of September 2010, when he experienced exc…
Sumit Kumar
Pancreas Divisum with secondary Chronic Pancreatitis
Dehradun, Uttarakhand
Sumit suffered from Pancreas Divisum, a congenital anomaly where the two pancreatic ducts (the ve…
Aviral Saxena
Chronic Pancreatitis with Secondary Diabetes
Dehradun, Uttarakhand
Aviral’s journey began in November 2022 while he was actively working as a freelancer. The …
Rajeev Sharma
Chronic Pancreatitis
Dehradun, Uttarakhand
Rajeev’s journey began with mild symptoms in 2009, potentially following a physical encount…
Research
Our Research
At Padaav, alongside delivering unparalleled patient care and promoting holistic health, we are committed to advancing Ayurveda by actively participating in research and contributing to its growing body of knowledge.
Case studies on prophylactic ayurvedic therapy in migraine patients
Ayurvedic treatment has shown effectiveness in managing migraines. A protocol (ATP) with herbo-mineral formulations, regular meals, and sleep reduced migraine frequency and intensity in a study of nine patients. Five reported significant improvement after 120 days, with no serious side effects. Ongoing research is further validating the findings.
Randomized Controlled Study to Evaluate Prophylactic Properties of Ayurvedic Treatment Protocol in Refractory and Chronic Migraine Patients
This study compared Ayurvedic treatment to conventional therapy for chronic refractory migraine. After 360 days, the Ayurvedic group showed greater reductions in headache days, VAS, and MIDAS scores (p
Treatment of relapsed undifferentiated acute myeloid leukemia (AML-M0) with Ayurvedic therapy
A 16-year-old boy with AML-M0 relapsed after chemotherapy in 1997. He opted for Ayurvedic therapy (AYT) instead of further treatment. After six months, he was in remission and continued AYT for five years, with intermittent maintenance for two years. He has been disease-free and healthy for 12 years.
Anti-Inflammatory Properties of a Processed Copper Complex in L-Arginine Induced Pancreatitis-Two Experimental Studies
Recurrent Acute/Chronic Pancreatitis (RA/CP) is a progressive pancreatic inflammation, often with unclear causes. An Ayurvedic Mineral Complex (AMC) showed promise in reducing exacerbations and hospitalizations in pancreatitis patients. In a rat model, AMC was well tolerated, reduced oxidative stress and inflammation, and protected the pancreas at doses of 25 mg/kg and 19 mg/kg.
Acute Promyelocytic Leukemia: 37 Years Long Ongoing Survival in a de novo Patient with Metal-Based Ayurvedic Treatment
Acute promyelocytic leukemia (APML) is a subtype of leukemia marked by anemia, infections, and bleeding. It is diagnosed through bone marrow tests and the PML-RARα fusion gene. Recent treatments with ATRA and arsenic trioxide have improved survival rates, but challenges like side effects and relapses remain. A 1982 case of a patient who survived 37 years without standard treatment suggests potential alternative therapies.
Ayurvedic treatment protocol in the management of pancreatitis: A nonrandomized observational study
A North Indian clinic treated 1750 recurrent pancreatitis patients (1997–2023) with an ayurvedic Herbo-Mineral Formulation (HMF). Among 916 completing 1-year treatment, attacks reduced by 93%, hospitalizations by 97%, with no adverse effects. Long-term remission supports further clinical trials.